title: Improvement of glycemic control in streptozotocin-induced diabetic rats by Atlantic salmon skin gelatin hydrolysate as the dipeptidyl-peptidase IV inhibitor.
abstract: In our previous study, Atlantic salmon skin gelatin hydrolysed with flavourzyme possessed 42.5% dipeptidyl-peptidase (DPP)-IV inhibitory activity at a concentration of 5 mg mL(-1). The oral administration of the hydrolysate (FSGH) at a single dose of 300 mg per day in streptozotocin (STZ)-induced diabetic rats for 5 weeks was evaluated for its antidiabetic effect. During the 5-week experiment, body weight increased, and the food and water intake was reduced by FSGH in diabetic rats. The daily administration of FSGH for 5 weeks was effective for lowering the blood glucose levels of diabetic rats during an oral glucose tolerance test (OGTT). After the 5-week treatment, plasma DPP-IV activity was inhibited; the plasma activity of glucagon-like peptide-1 (GLP-1), insulin, and the insulin-to-glucagon ratio were increased by FSGH in diabetic rats. The results indicate that FSGH has the function of inhibiting GLP-1 degradation by DPP-IV, resulting in the enhancement of insulin secretion and improvement of glycemic control in STZ-induced diabetic rats.
authors.affiliation: Department of Health and Nutrition Biotechnology, Asia University, Taiwan.
authors.forename: C H
authors.initials: CH
authors.lastname: Hsieh
authors.forename: T Y
authors.initials: TY
authors.lastname: Wang
authors.forename: C C
authors.initials: CC
authors.lastname: Hung
authors.forename: M C
authors.initials: MC
authors.lastname: Chen
authors.forename: K C
authors.initials: KC
authors.lastname: Hsu
mesh_terms: D000818:Animals; D001955:British Columbia; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000178:diet therapy* / Q000378:metabolism; D019587:Dietary Supplements / Q000191:economics; D018819:Dipeptidyl Peptidase 4 / Q000097:blood / Q000737:chemistry / Q000378:metabolism; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000191:economics / Q000302:isolation & purification / Q000378:metabolism / Q000627:therapeutic use*; D010450:Endopeptidases / Q000378:metabolism; D029941:Fish Proteins / Q000191:economics / Q000302:isolation & purification / Q000378:metabolism / Q000627:therapeutic use*; D005525:Food-Processing Industry / Q000191:economics; D005780:Gelatin / Q000191:economics / Q000302:isolation & purification / Q000378:metabolism / Q000627:therapeutic use*; D005934:Glucagon / Q000037:antagonists & inhibitors / Q000097:blood / Q000378:metabolism; D052216:Glucagon-Like Peptide 1 / Q000819:agonists / Q000097:blood / Q000378:metabolism; D006943:Hyperglycemia / Q000517:prevention & control; D007220:Industrial Waste / Q000032:analysis / Q000191:economics; D007328:Insulin / Q000819:agonists / Q000097:blood / Q000378:metabolism; D000078790:Insulin Secretion; D008297:Male; D011492:Protein Hydrolysates / Q000191:economics / Q000302:isolation & purification / Q000378:metabolism / Q000627:therapeutic use*; D017207:Rats, Sprague-Dawley; D020317:Salmo salar; D012867:Skin / Q000737:chemistry
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D029941:Fish Proteins; D007220:Industrial Waste; D007328:Insulin; D011492:Protein Hydrolysates; D052216:Glucagon-Like Peptide 1; D005780:Gelatin; D005934:Glucagon; D010450:Endopeptidases; C412470:flavourzyme; C000602659:DPP4 protein, rat; D018819:Dipeptidyl Peptidase 4